Scientific development in innovative therapies and precision medicine is evolving rapidly. More specifically, we are seeing potentially curative therapies not only in rare disease but also in development for prevalent conditions. We are currently at a turning point in Europe, where Regulators, policy makers and payers must adapt to address the dynamic environment and scientific evolution. Innovation in medicine only adds value when it reaches patients in time.

Who is This Track Designed For?

All developers of innovative therapies, precision medicines and diagnostics: global regulators, policy makers, industry leaders, academics, patients, HTA bodies representatives and payers.